The emergence of drug-resistant human immunodeficiency virus type 1 is a frequent cause of failure of combination therapies comprising reverse transcriptase and protease inhibitors. Rational design of salvage therapies requires new methods to assess drug susceptibility. A novel phenotypic drug susceptibility assay was developed and used to measure the drug susceptibilities of viruses obtained from 2 patients treated with zidovudine, lamivudine, and nelfinavir. Results showed that phenotypic drug resistance may be detectable before virus load rebound, treatment failure does not always imply viral resistance to all drugs in a treatment regimen, and persons with similar antiviral treatment histories and clinical courses may have different phenotypic drug resistance profiles at the time that treatment fails.
were quantitated by ultrasensitive bDNA or RT-polymerase chain reaction (PCR).
RNA extraction and patient sequence amplification. Virus was pelleted from 1-2 mL of plasma by centrifugation and disrupted in lysis buffer. RNA was isolated from the lysate by use of oligo(dT) magnetic beads (Dynal, Oslo), as described elsewhere [5] . Complementary DNA was prepared by use of Superscript II (Gibco BRL, Gaithersburg, MD) and amplified by PCR (Expand High Fidelity kit; Boehringer Mannheim, Indianapolis). Amplification primers flanked the regions of interest (PR and RT) and contained recognition sequences for restriction enzymes used for subsequent cloning. The resulting PCR products contained sequences from the 3 end of the gag open reading frame (ORF), including the p7/p1/ p6 cleavage sites, the PR ORF, and residues 1-305 of the RT ORF.
Resistance test vector library construction. Amplified DNA fragments were used to prepare resistance test vector (RTV) libraries representing patient virus populations. The recipient vector contained the luciferase gene in place of a portion of the HIV-1 envelope gene. A restriction site 5 of PR and one near the 3 end of the RT domain were used to insert patient-derived PR and RT sequences. Amplification products were digested and ligated to digested vector DNA. Ligation reactions were used to transform TOP10-competent Escherichia coli (InVitrogen, Carlsbad, CA). An aliquot of each transformation was plated, and the colonies were counted to obtain an estimate of the number of patient-derived clones represented in the RTV library (typically 500-10,000). Plasmid DNA was purified by use of QiaPrep columns (Qiagen, Valencia, CA).
Transfection and infection.
Human embryonic kidney cells (293) were transfected with a mixture of RTV DNA and an amphotropic murine leukemia virus envelope expression plasmid [6] by calcium phosphate precipitation. After transfection, the cells were trypsinized and replated in 96-well plates (transfection plates). Serial 4-fold dilutions of PR inhibitors (PRIs) were added to rows of the transfection plate to generate virus for PRI testing; medium without drug was added to other rows of the transfection plate to generate virus for RT inhibitor (RTI) testing. Cell culture supernatants were harvested 2 days after transfection, filtered, and used to infect fresh 293 cells in 96-well plates (infection plates). All infections were made in duplicate. Serial 4-fold dilutions of RTIs were added to rows of the infection plate for RTI testing; medium without drug was added to other rows of the infection plate for PRI testing by use of the virus generated in the presence of PRIs. Two days after infection, cells were lysed, and luciferase activity was measured. The percentage of inhibition of infection was determined by comparing luciferase activity in the presence and absence of drug. Mean percentage of inhibition values were determined by bootstrapping [7] and displayed as percentage of inhibition versus log 10 drug concentration. A standard 4-parametric sigmoidal function was fitted by use of a nonlinear least-square fit [8] . Drug susceptibilities are presented as mean IC 50 's from replicate assays. In reproducibility studies, 195% of replicate IC 50 's obtained by use of a drug-sensitive control (NL4-3) varied by !2.5-fold, suggesting that larger increases in IC 50 indicate reduced drug susceptibility.
Genotypic analysis. The nucleotide sequences of the patientderived inserts in the RTV libraries or in RTV clones obtained from the libraries were made by use of fluorescent dye-labeled dideoxy nucleotide sequencing (AmpliTaq sequencing kit; Perkin Elmer, Norwalk, CT) and analyzed on an automated sequencer (model 377; Applied Biosystems, Foster City, CA). Sequences were compared with lists of mutations correlated with drug resistance [9] .
Results
The efficacy of zidovudine, lamivudine, and nelfinavir was evaluated in a small-scale trial, involving 12 antiretroviral drug-naive patients [3] . In all patients, plasma HIV-1 RNA levels decreased to !500 copies/mL within 8 weeks after initiation of therapy, and CD4 cell counts eventually increased by ∼150 cells/mL (data not shown). In 2 patients, virus load subsequently rebounded to 1500 copies/mL at treatment months 11 (patient 1; 571 copies/mL) and 6 (patient 2; 692 copies/mL), indicating failure of therapy and suggesting the emergence of resistant virus. Retrospectively, it was determined that viral RNA levels in both patients had fallen below the detection limit (50 copies/mL) of a more sensitive virus load assay at months 3-4 but only transiently. Both patients reported good (195%) adherence and had plasma levels of drugs that were comparable with or greater than those determined in the other 10 patients who did not experience virus load rebound (data not shown). Plasma samples were selected to assess virus phenotype and genotype prior to initiation of therapy (baseline), during treatment prior to the rebound in virus load, and after rebound.
The plasma samples used for phenotypic and genotypic testing of virus from patient 1 were obtained at study months 0 (baseline), 7 (4 months before therapy failure), 10 (1 month before failure), and 12 (1 month after failure). The HIV-1 loads in plasma samples from months 0, 7, 10, and 12 were 84,900, !500, !500, and !500 copies/mL, respectively, as measured by the standard bDNA assay [10] ; however, the virus loads at months 7, 10, and 12 were 157, 385, and 1979 copies/mL, respectively, when tested by more sensitive assays [11, 12] . Drug susceptibility was evaluated by use of a novel rapid phenotypic assay. The assay utilizes RTV libraries containing patient virus-derived PR and RT sequences and a luciferase indicator gene and is run under conditions in which the RTV undergoes a single round of replication. Luciferase expression is dependent on the patient-derived PR and RT activities.
Phenotypic analysis of HIV in patient 1 demonstrated that baseline IC 50 's for all nucleoside RTIs and PRIs were similar to a drug-sensitive control virus (!2.5-fold difference between patient and control virus). The baseline IC 50 's for the nonnucleoside RTIs were about 2-to 4-fold higher than those for the control virus, probably due to polymorphisms in the virus from this drug-naive patient (differences between the baseline RT sequence and that of NL4-3 existed at positions 90, 98, 102, 162, 197, 211, 277, 283, and 293). At month 7, the IC 50 of nelfinavir had increased 3-fold above baseline (table 1, figure  1 ), but lamivudine and zidovudine IC 50 's were not significantly different from baseline (table 1) . At month 10, reduced susceptibility to both lamivudine and nelfinavir was demonstrated by 110-fold increases in IC 50 's for both drugs. At month 12, treatment failure was confirmed by 2 consecutive monthly plasma HIV RNA measurements (months 11 and 12) 1500 copies/mL. Virus from the 12-month plasma sample had decreased susceptibility to nelfinavir (15-fold) and lamivudine (IC 1 300 50 mM; 110-fold). There was no measurable zidovudine resistance or cross-resistance to antiretroviral drugs not used in the therapeutic regimen.
Despite a 3-fold increase in the IC 50 of nelfinavir, PR resistance mutations were not detected by sequencing the RTV pool from month 7. However, when individual clones were sequenced, 2 PR mutations (D30N and M36I) were detected in 1 of 8 clones (data not shown). The D30N mutation was previously found in viruses from persons in whom nelfinavir therapy failed [13] . A substitution at position 63 (LrP) of PR was present in all samples, including baseline, from patient 1. The lamivudine resistance-associated RT mutation (M184I) was found in 3 of 8 clones at month 7, including the clone with the D30N/M36I PR mutations. At months 10 and 12, PR mutations at the same 2 sites (D30N and M36I or M36L) and the M184V mutation in RT were detected both in pools and in each of the 5 clones sequenced from each time point. Mutations associated with zidovudine resistance (i.e., M41L, D67N, K70R, Q151M, L210W, T215Y, and K219Q) were not detected.
The plasma samples used for phenotypic and genotypic testing in patient 2 were obtained at baseline, month 5 (1 month before therapy failure), and month 10 (4 months after failure). The HIV-1 loads in the months 0, 5, and 10 plasma samples were 864,900, !500, and 6096 copies/mL, respectively, as measured by the standard bDNA assay; the virus load at month 5 was 612 copies/mL when reassayed by ultrasensitive RT-PCR. The phenotypic drug susceptibility analysis of HIV in patient 2 demonstrated that baseline IC 50 values for all RTIs and PRIs were similar to those of a drug-sensitive control virus (table 1) . Lamivudine resistance, first detected at month 5 (115-fold), had persisted at month 10. No decrease in susceptibility to nelfinavir or zidovudine was detected, nor was there measurable crossresistance to drugs not used in the therapeutic regimen (table 1, figure 1) .
At month 5, a mixture of M and V at position 184 in RT was detected in the pool from patient 2, while only V was present in all clones sequenced. At month 10, only M184V was detected in the pool and in the clones. At baseline, 2 of 5 clones contained the L10I mutation in PR. At month 10, most of the clones (5/6) and the majority of sequences represented in the pool contained the L90M mutation in PR. Mutations at positions 10 (L10I) and 23 (L23I) in PR were present at higher frequency in the month 10 sample (4/6 and 2/6, respectively) than at baseline, although these 2 mutations were not seen together in the same clone (data not shown). Mutations at position 36 (MrI) and 63 (LrH) of PR were present in all samples, including baseline, from patient 2. No known zidovudine resistance mutations were detected.
Discussion
Despite common clinical histories, antiviral treatment, and virologic outcomes, the virus populations in the 2 patients studied exhibited distinct phenotypic and genotypic profiles at the time of treatment failure. In patient 1, therapy failure was associated with reduced susceptibility to lamivudine and nelfinavir; in patient 2, only lamivudine resistance was detected. The different patterns of viral resistance seen in these 2 patients, and other patterns seen in patients in whom similar regimens failed (unpublished data), highlight the need for accurate and rapid assessment of drug susceptibility to determine appropriate salvage treatment strategies. In particular, if the virus remains susceptible to any of the drugs in the original therapeutic regimen, these drugs could be included in a salvage regimen. The observed differences in viral drug susceptibility in patients with similar treatment histories raise the possibility that multiple factors, including adherence to treatment regimens, drug absorption, metabolism, or an increase in the number of available target cells [14, 15] , may play a role in treatment failure.
The lack of a consistent correlation between combinations of known resistance mutations and drug susceptibility suggests that the interactions between mutations are complex. Mutations not known to be associated with resistance may play significant roles in determining viral drug susceptibility. For example, in patient 2, the presence of the L90M mutation did not result in reduced susceptibility to nelfinavir or saquinavir [9] . Both patients experienced virus load suppression (!500 copies/mL), which lasted у1 year after initiation of a salvage treatment regimen that included saquinavir and ritonavir, suggesting that for patient 2 the phenotype was more predictive of response than the genotype. Until there is a comprehensive understanding of the complex relationship between genotype and phenotype, phenotypic data provide the most direct and easily interpretable assessment of drug susceptibility.
Our results indicate, first, that phenotypic drug resistance can be detected before virologic failure of antiretroviral therapy (when failure is defined by repeated virus load measurements 1500 copies/mL). Second, failure of triple combination therapy is not always associated with resistance to all drugs in the regimen. Third, similar clinical and treatment histories can be associated with different phenotypic and genotypic profiles at the time of treatment failure. Until further clinical studies define the optimal strategies for incorporation of newer technologies into the clinical management of HIV-1 infection, a combination of phenotypic susceptibility data with other clinical and laboratory diagnostic information may provide the most complete assessment of appropriate treatment options for designing therapy regimens.
